Predicting development of proliferative diabetic retinopathy

Diabetes Care

Volumn 36, Issue 6, 2013, Pages 1562-1568

  Nwanyanwu, Kristen Harris ^a   Talwar, Nidhi ^a   Gardner, Thomas W ^a   Wrobel, James S ^a   Herman, William H ^a,b   Stein, Joshua D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROBABILITY; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84878225640     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0790     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States [article online], 2011. Available from http://www.cdc.gov/ diabetes/pubs/pdf/ndfs-2011.pdf. Accessed 6 February 2012
2. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010;304:649-656
3. Gabrielian A, Hariprasad SM, Jager RD, Green JL, Mieler WF. The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life. Eye (Lond) 2010;24:29-35
4. Fong DS, Aiello L, Gardner TW, et al.; American Diabetes Association. Retinopathy in diabetes. Diabetes Care 2004;27(Suppl. 1):S84-S87 (Pubitemid 38197476)
5. Mazhar K, Varma R, Choudhury F, McKean-Cowdin R, Shtir CJ, Azen SP; Los Angeles Latino Eye Study Group. Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study. Ophthalmology 2011;118:649-655
6. Schmier JK, Covert DW, Lau EC, Matthews GP. Medicare expenditures associated with diabetes and diabetic retinopathy. Retina 2009;29:199-206
7. Woung LC, Tsai CY, Chou HK, et al. Healthcare costs associated with progressive diabetic retinopathy among National Health Insurance enrollees in Taiwan, 2000-2004. BMC Health Serv Res 2010;10:136
8. Hirsch IB, Brownlee M. Beyond hemoglobin A1c - need for additional markers of risk for diabetic microvascular complications. JAMA 2010;303:2291-2292
9. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815 (Pubitemid 28509717)
10. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631-1640 (Pubitemid 39473407)
11. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244
12. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739-745
13. Gordon MO, Torri V, Miglior S, et al.; Ocular Hypertension Treatment Study Group; European Glaucoma Prevention Study Group. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007;114:10-19
14. Physician International Classification of Diseases. International Classification of Diseases, 9th Edition,Clinical Modification.Vol. 1 and 2. Chicago, IL, American Medical Association Press, 2006
15. CPT 2006: Current Procedural Terminology. Professional Edition. Chicago, IL, American Medical Association Press, 2006
16. Newman-Casey PA, Talwar N, Nan B, Musch DC, Stein JD. The relationship between components of metabolic syndrome and open-angle glaucoma. Ophthalmology 2011;118:1318-1326
17. Stein JD, Vanderbeek BL, Talwar N, Nan B, Musch DC, Zacks DN. Rates of non-exudative and exudative age-related macular degeneration among Asian American ethnic groups. Invest Ophthalmol Vis Sci 2011;52:6842-6848
18. Muir KW, Gupta C, Gill P, Stein JD. Accuracy of International Classification of Diseases, Ninth Revision, Clinical Modification billing codes for common ophthalmic conditions. JAMA Ophthalmol 2013;131:119-120
19. Allison PD. Survival Analysis Using SAS: A Practical Guide. 2nd ed. Cary, NC, SAS Institute, 2010
20. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999;20:145-157 (Pubitemid 29242575)
21. Cikamatana L, Mitchell P, Rochtchina E, Foran S, Wang JJ. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. Eye (Lond) 2007;21:465-471 (Pubitemid 46564136)
22. Roy MS, Affouf M. Six-year progression of retinopathy and associated risk factors in African American patients with type 1 diabetes mellitus: the New Jersey 725. Arch Ophthalmol 2006;124:1297-1306 (Pubitemid 44379864)
23. Vitale S, Maguire MG, Murphy RP, et al. Interval between onset of mild non-proliferative and proliferative retinopathy in type I diabetes. Arch Ophthalmol 1997;115:194-198 (Pubitemid 27083792)
24. Wong TY, Mwamburi M, Klein R, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32:2307-2313
25. Porta M, Sjoelie AK, Chaturvedi N, et al.; EURODIAB Prospective Complications Study Group. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001;44:2203-2209 (Pubitemid 34015473)
26. Valsania P, Warram JH, Rand LI, Krolewski AS. Different determinants of neovascularization on the optic disc and on the retina in patients with severe non-proliferative diabetic retinopathy. Arch Ophthalmol 1993;111:202-206 (Pubitemid 23053568)
27. Roy MS, Janal MN. High caloric and sodium intakes as risk factors for progression of retinopathy in type 1 diabetes mellitus. Arch Ophthalmol 2010;128:33-39
28. Roy MS, Klein R, Janal MN. Retinal venular diameter as an early indicator of progression to proliferative diabetic retinopathy with and without high-risk characteristics in African Americans with type 1 diabetes mellitus. Arch Ophthalmol 2011;129:8-15
29. Leese GP, Cochrane L, Mackie AD, Stang D, Brown K, Green V. Measuring the accuracy of different ways to identify the 'at-risk' foot in routine clinical practice. Diabet Med 2011;28:747-754
30. Leymarie F, Richard JL, Malgrange D. Factors associated with diabetic patients at high risk for foot ulceration. Diabetes Metab 2005;31:603-605 (Pubitemid 43001180)
31. Moss SE, Klein R, Klein BE. Long-term incidence of lower-extremity amputations in a diabetic population. Arch Fam Med 1996;5:391-398 (Pubitemid 126445125)
32. Moss SE, Klein R, Klein BE; The Wisconsin Study of Diabetic Retinopathy. The 14-year incidence of lower-extremity amputations in a diabetic population. Diabetes Care 1999;22:951-959
33. Moss SE, Klein R, Klein BE, Wong TY. Retinal vascular changes and 20-year incidence of lower extremity amputations in a cohort with diabetes. Arch Intern Med 2003;163:2505-2510 (Pubitemid 37385794)
34. Hämäläinen H, Rönnemaa T, Halonen JP, Toikka T. Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: a population-based 7-year follow-up study. J Intern Med 1999;246:97-103 (Pubitemid 29327358)
35. Mayfield JA, Reiber GE, Nelson RG, Greene T. A foot risk classification system to predict diabetic amputation in Pima Indians. Diabetes Care 1996;19:704-709 (Pubitemid 26249720)
36. Landis RC, Evans BJ, Chaturvedi N, Haskard DO. Persistence of TNFalpha in diabetic wounds. Diabetologia 2010;53:1537-1538
37. Oncul O, Yildiz S, Gurer US, et al. Effect of the function of polymorphonuclear leukocytes and interleukin-1 beta on wound healing in patients with diabetic foot infections. J Infect 2007;54:250-256 (Pubitemid 46238168)
38. Acosta JB, del Barco DG, Vera DC, et al. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J 2008;5:530-539
39. Meleth AD, Agrón E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46:4295-4301 (Pubitemid 44264635)
40. Huijberts MS, Schaper NC, Schalkwijk CG. Advanced glycation end products and diabetic foot disease. Diabetes Metab Res Rev 2008;24(Suppl. 1):S19-S24 (Pubitemid 351802767)
41. Meerwaldt R, Links TP, Graaff R, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005;48:1637-1644 (Pubitemid 41175518)
42. Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49:2679-2685
43. Aspelund T, Thornórisdóttir Ó, Ólafsdottir E, et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 2011;54:2525-2532